Marijuana improved motor impairments and changes in synaptic plasticity-related molecules in the striatum in 6-OHDA-treated rats

Komeili, Gholamreza; Haghparast, Elham; Sheibani, Vahid

doi:10.1016/j.bbr.2021.113342

Cited by 9 publications

(13 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cannabinoid interventions from included studies varied from cannabinoid receptor (CBR) agonists such as HU308, CBD, WIN55,212–2, HU210, nabilone, THC, CP55,940, ACEA, CBGA-quinone (CBGA-Q), GW842166x and AM1241,20 23 24 26–52 endocannabinoid enzyme inhibitors (FAAH and MAGL) which increase available endocannabinoids such as JZL184, URB597, KML29, PF-3945,19 21 22 25 29 34 45 53–56 a putative endocannabinoid, noladin ether which is an endocannabinoid agonist,32 57 58 an endocannabinoid modulator blocking anandamide reuptake called AM40459 preserves the supply of endocannabinoids and beta-caryophellene, which is a terpene commonly found in cannabis 60…”

Section: Resultsmentioning

confidence: 99%

“…18 Seven studies measured both rotarod and pole tests 19 20 22 30 41 50 53. Two additional studies measured rotarod31 47 only, giving a total of nine studies included in the meta-analysis. There was also one additional study45 that assessed pole test only giving eight studies in the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

“…Of the nine studies in the rotarod meta-analysis, eight used toxin-based rodent models of PD19 22 30 31 41 47 50 53 while seven of the eight studies in pole meta-analysis used toxin-based rodent models 19 22 30 41 45 50 53. One study (included in both rotarod and pole test groups)20 used a transgenic PD animal model.…”

Section: Resultsmentioning

confidence: 99%

“…Nine studies19 20 22 30 31 41 47 50 53 performed rotarod tests and were considered for meta-analysis. Cannabinoid interventions used varied: URB597, an FAAH inhibitor,53 JZL184 and KML29, both MAGL inhibitors,19 22 and CBD, HU308, HU210, THC, GW842166x and AM1241, all CB agonists 20 30 31 41 47 50.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Effects of cannabinoids in Parkinson’s disease animal models: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

ObjectivesCannabis has been proposed as a potential treatment for Parkinson’s disease (PD) due to its neuroprotective benefits. However, there has been no rigorous review of preclinical studies to evaluate any potential treatment effect. This systematic review was undertaken to provide evidence in support or against a treatment effect of cannabinoids in animal models of PD.MethodsDatabases were searched for any controlled comparative studies that assessed the effects of any cannabinoid, cannabinoid-based treatment or endocannabinoid transport blocker on behavioural symptoms in PD animal models.ResultsA total of 41 studies were identified to have met the criteria for this review. 14 of these studies were included in meta-analyses of rotarod, pole and open field tests. Meta-analysis of rotarod tests showed a weighted mean difference of 31.63 s for cannabinoid-treated group compared with control. Meta-analysis of pole tests also showed a positive treatment effect, evidenced by a weighted mean difference of −1.51 s for cannabinoid treat group compared with control. However, meta-analysis of open field test demonstrated a standardised mean difference of only 0.36 indicating no benefit.ConclusionThis review demonstrates cannabinoid treatment effects in alleviating motor symptoms of PD animal models and supports the conduct of clinical trials of cannabis in PD population. However, there is no guarantee of successful clinical translation of this outcome because of the many variables that might have affected the results, such as the prevalent unclear and high risk of bias, the different study methods, PD animal models and cannabinoids used.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Effects of cannabinoids in Parkinson’s disease animal models: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Since movements are impaired and slow in Parkinson's disease patients, it spurs us to select reliable behavioral parameters to reveal important information on potential behaviors of drug action, and then characterize the extent of the lesion and therapeutic effects. Previous studies have shown that the beam walking or balance test is a useful assessment of motor coordination of rodents (Karl et al, 2003;Quinn et al, 2007;Curzon et al, 2009;Komeili et al, 2021). Here, we made some modifications to parameters of the beam walking test, that is, recording time from the starting area to 20 cm and the starting to the end point are considered as latency time and total time, respectively.…”

Section: Discussionmentioning

confidence: 99%

5-(4-Hydroxy-3-dimethoxybenzylidene)-thiazolidinone improves motor functions and exerts antioxidant potential in hemiparkinsonian rats

Ren

Ding

Zhou

et al. 2022

Behavioural Pharmacology

View full text Add to dashboard Cite

Our previous study demonstrated that 5-(4-hydroxy-3-dimethoxybenzylidene)-thiazolidinone (RD-1), one of rhodamine derivatives, significantly improves motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model and could minimize mitochondrial impairment, which is a potential therapeutic target to slow down the dopaminergic neurodegeneration in Parkinson’s disease. To further evaluate its therapeutic and antioxidative potential in Parkinson’s disease, the current study was designed to explore the effect of RD-1 on hemiparkinsonian rats following unilateral 6-hydroxydopamine lesions. Motor functional behavioral tests, including apomorphine-induced rotational analysis and beam walking tests, were assessed. Our results showed that oral RD-1 administration for 2 weeks alleviated beam walking disability, but not the rotational behavior. Furthermore, compared to the sham group, tyrosine hydroxylase- (TH-) positive neurons in the substantia nigra pars compacta and fibers in the striatum were significantly preserved in the RD-1 treatment group. The abnormal activities of superoxide dismutase, catalase, and glutathione peroxidase and contents of MDA were evidently ameliorated by RD-1, at least partly. We conclude that RD-1 could improve motor functions and alleviate the loss of dopaminergic expression in the nigrostriatal pathway of Parkinson’s disease rats, and the protective mechanism of RD-1 against neurodegeneration was possibly via its modulation of antioxidation.

show abstract

The Effects of Chronic Marijuana Administration on 6-OHDA-Induced Learning & Memory Impairment and Hippocampal Dopamine and Cannabinoid Receptors Interaction in Male Rats

et al. 2023

View full text Add to dashboard Cite

Marijuana improved motor impairments and changes in synaptic plasticity-related molecules in the striatum in 6-OHDA-treated rats

Cited by 9 publications

References 68 publications

Effects of cannabinoids in Parkinson’s disease animal models: a systematic review and meta-analysis

Effects of cannabinoids in Parkinson’s disease animal models: a systematic review and meta-analysis

5-(4-Hydroxy-3-dimethoxybenzylidene)-thiazolidinone improves motor functions and exerts antioxidant potential in hemiparkinsonian rats

The Effects of Chronic Marijuana Administration on 6-OHDA-Induced Learning & Memory Impairment and Hippocampal Dopamine and Cannabinoid Receptors Interaction in Male Rats

Contact Info

Product

Resources

About